Novanta Inc NOVT
We take great care to ensure that the data presented and summarized in this overview for NOVANTA INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NOVT
View all-
Black Rock Inc. New York, NY4.41MShares$695 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.06MShares$641 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.07MShares$326 Million0.04% of portfolio
-
Conestoga Capital Advisors, LLC1.35MShares$213 Million2.95% of portfolio
-
State Street Corp Boston, MA1.3MShares$205 Million0.01% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT1.01MShares$159 Million0.79% of portfolio
-
William Blair Investment Management, LLC Chicago, IL964KShares$152 Million0.39% of portfolio
-
Alliancebernstein L.P. New York, NY946KShares$149 Million0.05% of portfolio
-
Neuberger Berman Group LLC New York, NY883KShares$139 Million0.11% of portfolio
-
Geode Capital Management, LLC Boston, MA875KShares$138 Million0.01% of portfolio
Latest Institutional Activity in NOVT
Top Purchases
Top Sells
About NOVT
Novanta Inc., together with its subsidiaries, designs, manufactures, markets, and sells photonics, vision, and precision motion components and sub-systems to original equipment manufacturers in the medical and industrial markets worldwide. The company's Photonics segment offers photonics-based solutions, including laser scanning and beam delivery, CO2 laser, solid state laser, ultrafast laser, and optical light engine products serving photonics-based applications for industrial processing, metrology, medical and life science imaging, DNA sequencing, and medical laser procedures. It's Vision segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; visualization solutions; wireless technologies, video recorders, and video integration technologies for operating room integrations; optical data collection and machine vision technologies; radio frequency identification technologies; thermal chart recorders; spectrometry technologies; and embedded touch screen solutions. In addition, its Precision Motion segment offers optical and inductive encoders, precision motors, servo drives and motion control solutions, integrated stepper motors, intelligent robotic end-of-arm technology solutions, air bearings, and air bearing spindles. The company sells its products through its direct sales force, resellers, distributors, and system integrators under the Cambridge Technology, Synrad, Laser Quantum, ARGES, WOM, NDS, NDSsi, Med X Change, Reach Technology, JADAK, ThingMagic, Photo Research, Celera Motion, MicroE, Zettlex, Applimotion, Ingenia, and Westwind brands. The company was formerly known as GSI Group, Inc. and changed its name to Novanta Inc. in May 2016. Novanta Inc. was founded in 1968 and is headquartered in Bedford, Massachusetts.
Insider Transactions at NOVT
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Nov 11
2024
|
Matthijs Glastra Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
7,500
-2.45%
|
$1,350,000
$180.61 P/Share
|
Nov 06
2024
|
Robert Buckley Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,660
-1.48%
|
$658,800
$180.79 P/Share
|
Nov 06
2024
|
Robert Buckley Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,660
+2.87%
|
$51,240
$14.13 P/Share
|
Nov 01
2024
|
Robert Buckley Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,660
-0.6%
|
$629,520
$172.91 P/Share
|
Nov 01
2024
|
Robert Buckley Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,660
+2.87%
|
$51,240
$14.13 P/Share
|
Oct 01
2024
|
Robert Buckley Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,660
-0.59%
|
$640,500
$175.09 P/Share
|
Oct 01
2024
|
Robert Buckley Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,660
+2.87%
|
$51,240
$14.13 P/Share
|
Sep 27
2024
|
Robert Buckley Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,111
-0.91%
|
$199,980
$180.45 P/Share
|
Sep 27
2024
|
Robert Buckley Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,111
+0.91%
|
$15,554
$14.13 P/Share
|
Sep 05
2024
|
Matthijs Glastra Chief Executive Officer |
BUY
Bona fide gift
|
Indirect |
19,572
+32.05%
|
-
|
Sep 05
2024
|
Matthijs Glastra Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
19,572
-100.0%
|
-
|
Sep 05
2024
|
Matthijs Glastra Chief Executive Officer |
SELL
Bona fide gift
|
Indirect |
5,778
-20.86%
|
-
|
Sep 03
2024
|
Robert Buckley Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,379
-0.51%
|
$779,462
$178.02 P/Share
|
Sep 03
2024
|
Robert Buckley Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,379
+3.39%
|
$61,306
$14.13 P/Share
|
Aug 15
2024
|
Robert Buckley Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,382
-1.13%
|
$248,760
$180.25 P/Share
|
Aug 15
2024
|
Robert Buckley Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,382
+1.12%
|
$19,348
$14.13 P/Share
|
Aug 15
2024
|
Michele Davis Welsh General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
590
-28.53%
|
$106,200
$180.4 P/Share
|
Aug 15
2024
|
Michele Davis Welsh General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
1,329
+39.12%
|
-
|
Aug 01
2024
|
Robert Buckley Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,108
-0.33%
|
$710,684
$173.95 P/Share
|
Aug 01
2024
|
Robert Buckley Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,108
+3.19%
|
$57,512
$14.13 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 58.5K shares |
---|---|
Grant, award, or other acquisition | 33.5K shares |
Bona fide gift | 19.6K shares |
Payment of exercise price or tax liability | 27K shares |
---|---|
Open market or private sale | 85.5K shares |
Bona fide gift | 25.4K shares |